Fidelity Investments’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-35,061
| Closed | -$55.7K | – | 5743 |
|
|
2024
Q1 | $55.7K | Sell |
35,061
-32,430
| -48% | -$48.1K | ﹤0.01% | 3531 |
|
|
2023
Q4 | $58K | Buy |
67,491
+5,778
| +9% | +$5.07K | ﹤0.01% | 3456 |
|
|
2023
Q3 | $66K | Buy |
61,713
+13,565
| +28% | +$28.1K | ﹤0.01% | 3260 |
|
|
2023
Q2 | $125K | Buy |
48,148
+1,142
| +2% | +$4.07K | ﹤0.01% | 3089 |
|
|
2023
Q1 | $192K | Buy |
47,006
+611
| +1% | +$2.82K | ﹤0.01% | 2997 |
|
|
2022
Q4 | $233K | Sell |
46,395
-4,277,806
| -99% | -$26.8M | ﹤0.01% | 2961 |
|
|
2022
Q3 | $56.6M | Buy |
4,324,201
+2,263,668
| +110% | +$34.3M | 0.01% | 1201 |
|
|
2022
Q2 | $26.4M | Buy |
2,060,533
+787,347
| +62% | +$10.9M | ﹤0.01% | 1540 |
|
|
2022
Q1 | $19.4M | Sell |
1,273,186
-27,952
| -2% | -$436K | ﹤0.01% | 1792 |
|
|
2021
Q4 | $23M | Sell |
1,301,138
-6,799
| -0.5% | -$130K | ﹤0.01% | 1756 |
|
|
2021
Q3 | $27.5M | Buy |
+1,307,937
| New | +$28.8M | ﹤0.01% | 1684 |
|
|
2019
Q4 | – | Sell |
-288,200
| Closed | -$3.99M | – | 4358 |
|
|
2019
Q3 | $3.99M | Hold |
288,200
| – | – | ﹤0.01% | 2113 |
|
|
2019
Q2 | $4.22M | Buy |
+288,200
| New | +$4.22M | ﹤0.01% | 2143 |
|
Fidelity Investments's NGM Position: Q2 2024 in Review
Fidelity Investments sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 35,061 shares — an estimated $55.7K sold.
Fidelity Investments first reported a position in NGM in Q2 2019 and held it in 13 quarters. The position peaked at $56.6M in Q3 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Fidelity Investments reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Fidelity Investments sold 35,061 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $55.7K.
- Fidelity Investments first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- Fidelity Investments's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $56.6M in Q3 2022.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Fidelity Investments's 13F filing for Q2 2024, filed 13 Aug 2024.